Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trial.
Simon ParlowPietro Di SantoLee H SterlingLaura GoodliffePouya MotazedianGraeme Prosperi-PortaBaylie MorganZandra KoopmanRichard G JungMelissa Fay Lepage-RatteLisa RobinsonHannah FeaganTrevor SimardGeorge A WellsKwadwo KyeremantengCraig AinsworthFaizan AminJeffrey A MarbachShannon M FernandoMarino LabinazEmilie P Belley-CoteBenjamin HibbertRebecca MathewPublished in: American heart journal (2023)
This trial will be the first to establish the safety and efficacy of inotrope therapy against placebo in a population of patients with CS and has the potential to alter the standard care provided to this group of patients.